FROM RADIOBIOLOGY TO RADIATION ONCOLOGY

This book offers a wide perspective on the fundamental and state-of-the-art knowledge in radiobiology, radiation oncology, and the connection between both fields. Chapters incorporate basic concepts of cancer biology and radiobiology with advances in radiotherapy in cancer treatment for various types of cancer. Chapters review one or more areas of radiation oncology with topics ranging from the application of radiotherapy in various cancers, the use of advanced techniques such as FLASH radiotherapy, applications of artificial intelligence in treatment planning, and more importantly, the current and potential strategies to reduce the toxic effects of radiation. This book incorporates interdisciplinary concepts by exploring recent approaches like radiogenomics for personalizing radiotherapy and the effects of the microbiome on radiation research.

Teaching the basics of radiobiology and connections between the theory and the practical aspects of radiotherapy techniques, this book is a useful reference for cancer researchers, practitioners, interdisciplinary researchers in related fields, and students in radiation oncology and radiobiology. Through this integration of strong scientific foundations and clinical applicability, this book provides future research directions and rationales for readers looking to expand their knowledge about radiation with the most recent and essential data on the subject.

Dr. Farzad Taghizadeh-Hesary, M.D., is an Assistant Professor of Radiation Oncology at the Iran University of Medical Sciences. His research and clinical expertise lie at the intersection of radiation oncology, radiobiology, and cancer metabolism. Dr. Taghizadeh-Hesary's work focuses on integrating the tumor microenvironment and mitochondrial metabolism into cancer research and personalized radiotherapy. He has published over 90 peer-reviewed articles in high-impact journals and serves on the editorial boards of leading oncology journals. Dr. Taghizadeh-Hesary has received numerous awards, including the prestigious Razi Medical Science Research Prize. With a deep understanding of the complex interplay between radiation, tumor biology, and metabolic pathways, Dr. Taghizadeh-Hesary's work aims to develop innovative strategies for improving cancer treatment outcomes and enhancing the quality of life for patients.

Sumel Ashique has been working as an assistant professor at Department of Pharmaceutical Technology, Bharat Technology, Uluberia-711316, West Bengal, India. He has knowledge in drug delivery, nanotechnology and targeted treatment strategy. Currently he has edited 18+ books under CRC Press, Taylor and Francis, Wiley, Nova Science and Springer.

Dr. Neeraj Mishra is working as Professor in Amity Institute of Pharmacy, Gwalior since July 2019. He has around twenty years of teaching and research experience. He has more than 100 publications of International and National repute in recent concepts of novel drug delivery systems, localized drug delivery, targeted and controlled drug delivery of nanocarriers/ microparticles for the treatment of breast, colon cancer, and neurodegenerative disorders.

Dr. Babak Behnam is a Research Faculty in biology and genomic medicine at American University and Professor at the Floret Genomic Center. He earned his M.D. from Iran University of Medical Sciences (IUMS) in 1997 before specializing in genomic medicine, completing an M.Sc. in Molecular Medicine at the University of Sheffield and a Ph.D. in Human Genetics at University College London (UCL) in 2005. After his Ph.D., Dr. Behnam moved to the U.S., where he was awarded an NIH-based Ruth L. Kirschstein NRSA fellowship and completed four years of postdoctoral training at the University of Michigan and the University of Central Florida. His research focuses on molecular metastatic pathways, cancer biology, and mitochondrial genetics. At IUMS, he served as Associate Professor of Human Genetics, established and directed the medical genetics laboratory at OB/GYN and Children’s University Hospitals for seven years, and taught and mentored numerous students. Upon returning to the U.S., Dr. Behnam joined the NIH Undiagnosed Disease Program while completing an ABMGG-accredited clinical biochemical genetics fellowship at NHGRI, NIH. He later transitioned to Regulatory Affairs at NSF International, overseeing FDA submissions and compliance. As Co-Founder and Chief Scientific Officer (CSO) of Avicenna Biotech Research, he leads IP strategy and serves as a Medical Science Liaison (MSL). A prolific academic, Dr. Behnam has authored over 80 peer-reviewed publications, contributed to several chapters of five books, and holds editorial roles at MDPI Cancers and Frontiers. He also holds multiple patents in addiction therapies and cancer therapeutics.